Product Images Rivastigmine

This appears to be a chart showing the concentration of Rivastigmine (in ng/mL) at different dosages (4.6 mg/24 hours, 9.5 mg/24 hours, and 13.3 mg/24 hours). The number of participants in each dosage group is also listed.*

This is a description of a clinical trial of Rivastigmine Transdermal System. The graph shows improvement or decline in clinical factors over a period of 52 weeks with treatment, with significant improvement at the 133mg/24hr dosage compared to the 9.5mg/24hr dosage.*

This is a graph that illustrates clinical improvement in patients receiving either 13.3 mg/24hr or 9.5mg/24 hr of Rivastigmine Transdermal System treatment over several weeks. The Y-axis represents clinical improvement, while the X-axis depicts the number of weeks of treatment. The graph shows a decline in clinical improvement for both treatment groups, but the decline was significantly less in the group receiving the 13.3 mg/24hr dosage compared to those receiving the 9.5 mg/24hr dosage.*

This is a clinical study that compares the effectiveness of two types of rivastigmine transdermal system (13.3 mg/24 hr and 4.6 mg/24 hr) in improving symptoms over a period of 16 weeks. The results are presented in a table featuring statistical measures such as LS mean diff, Improvement, p-values, and the LS Mean change. The LS means and standard errors are based on an analysis of covariance model. The study found that the 13.3 mg/24 hr system had a higher LS mean improvement than the 4.6 mg/24 hr system but statistical significance was only demonstrated for some of the measures.*

This text appears to be a statistical analysis of a clinical trial for a treatment using Rivasligmine Transdermal System. The table shows the mean difference and standard error for clinical improvement and decline, as well as the results of statistical significance testing. The analysis was adjusted for pooled center and baseline. There are no available details on the clinical trial design, sample size, or patient characteristics.*

This is a product description of a transdermal system for delivering Rivastigmine medicine. The system is applied to the skin and contains an adhesive layer protected by a protective liner. The product is designed for transdermal use only.*

This appears to be a diagram or image showing different body parts, including the left or right upper arm, left or right side of the chest, left or right upper back, and left or right lower back. It also mentions the front and back of the body, but the context is not clear.*

Protective liners are likely used to cover and protect the sticky surface of a transdermal system. However, without further information, it is difficult to provide a more detailed description.*

This is a set of instructions for disposing of a slide folded patch. The patch should be placed in the trash, and its sticky sides should be folded together and placed into an empty pouch. This pouch should be kept away from children and pets.*

This text provides instructions for removing and discarding Rivastigmine Transdermal System patches, including folding the used patch and discarding it out of reach of children. The text also includes information on the dosage and administration, inactive components, and manufacturing information. There are warnings to keep the patch out of reach of children and not to use any damaged or tampered patches.*

The given text provides instructions on how to discard the Rivastigmine Transdermal System patch safely. The old patch should be removed every 24 hours and put in its original pouch. The pouch should be kept out of the reach of children, and hands should be washed with soap and water. The text also includes details on the inactive components and dosage and administration, as well as the manufacturer's name and address. It also warns users to not use any patch that is damaged or shows signs of tampering.*

This is a set of instructions for the use and disposal of the Rivastigmine Transdermal System, which is a medication patch to treat Alzheimer's disease. The patch should be replaced every 24 hours, and the used patch should be folded and safely discarded out of the reach of children. The patch contains 20.16 mg of rivastigmine USP to provide 13.3 mg of the medication every 24 hours. The patch should be applied immediately after removal from its pouch, and should not be used if damaged or tampered with. The manufacturer is Northstar Rx LLC, and the patch is made by Cadila Healthcare Limited in India.*